Oral Cancer

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

P=N/A, N=97, Completed, Institut Cancerologie de l'Ouest | Unknown status --> Completed | Phase classification: P3 --> PN/A

This approach achieved 84.7% tumor inhibition and prolonged survival in an orthotopic OSCC model. This work presents a chemical strategy that addresses fundamental CDT limitations through cascade catalysis with atomic-level tunability.

Functional correlation analyses suggested that these biomarkers may be associated with an immunosuppressive tumor microenvironment by modulating the infiltration pattern of immune cells. Collectively, these findings characterize the salivary proteomic changes associated with OLK-OSCC and identify a five-protein salivary panel with potential value for OLK surveillance and early detection of malignant transformation.

Remarkably, a study using an elastomeric platform for coculture of patient-derived cancer and cancer-associated fibroblast (CAF) cells shows a significant reduction in CAFs' ability to infiltrate and compartmentalize the tumor core as well as encapsulate the tumor upon US treatment. Our findings suggest that an ultrasound-based strategy could be used to target the oral tumor microenvironment to augment existing cancer treatment and may open avenues for broader application in superficial malignancies.

P=N/A, N=200, Recruiting, Stanford University | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Jun 2027

P1, N=40, Recruiting, Vanderbilt-Ingram Cancer Center | Not yet recruiting --> Recruiting

Notch-1 and Notch-3 are useful prognosticators; however, Notch-1 acts as a tumor suppressor, whereas, Notch-3 acts as an oncogene correlating with aggressive phenotype. Therefore, it is very important to study both markers for OSCC patients to add prognostic information and thereby help guide therapeutic decisions.

The precise role of hormones in OSCC has been less explored in the literature. Therefore, the significant expression of ERα and PR observed in dysplastic and OSCC groups in this study may elucidate their roles in tumor development and progression.

Given the challenges in diagnosis and the potential for rapid recurrence or metastasis, early detection is crucial. Comprehensive genomic profiling is highly desirable, as genomic analysis may direct the development of targeted therapeutic agents to treat relapse.

CLTC may serve as a prognostic biomarker in OSCC and may contribute to tumor progression by promoting malignant cellular phenotypes and immunosuppressive remodeling of the tumor microenvironment. Future mechanistic studies are required to determine whether CLTC directly regulates chemotherapy response through clathrin-mediated trafficking, receptor recycling, adhesion signaling, or tumor-immune interactions.

Our study presents a single-cell atlas of AoV carcinoma, highlighting the molecular diversity of malignant epithelium and its association with the immune microenvironment. The PB-KRAS subtype emerges as a stem-like, immunosuppressive tumor state associated with poor prognosis, providing insights for future therapeutic targeting.